Literature DB >> 27718209

Lipopolysaccharide Binding Protein and Oxidative Stress in a Multiple Sclerosis Model.

Begoña M Escribano1,2, Francisco J Medina-Fernández2,3, Macarena Aguilar-Luque2,3, Eduardo Agüera2,4, Montserrat Feijoo2,3, Fe I Garcia-Maceira5, Rafael Lillo2,6, Patricia Vieyra-Reyes7, Ana I Giraldo2,3, Evelio Luque2,8, René Drucker-Colín9, Isaac Túnez10,11,12.   

Abstract

Recent findings in experimental autoimmune encephalomyelitis (EAE) suggest that altering certain bacterial populations present in the gut may lead to a proinflammatory condition, that could result in the development of multiple sclerosis (MS). Also, Reactive Oxygen Species seem to be involved in the course of MS. In this study, it has been aimed to relate all these variables starting from an analysis of the lipopolysaccharide (LPS) and LPS-binding protein (LBP) with the determination of parameters related to oxidative stress in the blood, brain and spinal cord. For this purpose, samples obtained from EAE rats and relapsing-remitting (RRMS) MS patients were used. In addition, EAE rats were treated with Natalizumab, N-acetyl-cysteine and dimethyl fumarate. Natalizumab was also employed in RRMS. The results of this study revealed an improvement in the clinical symptoms of the EAE and MS with the treatments, as well as a reduction in the oxidative stress parameters and in LBP. Correlations between the clinical variables of the disease, i.e. oxidative damage and LBP, were established. Although the conclusions of this research are indeed relevant, further investigation would be necessary to establish the intrinsic mechanisms of the MS-oxidative stress-microbiota relationship.

Entities:  

Keywords:  Dimethyl fumarate; Experimental autoimmune encephalomyelitis; Lipopolysaccharide binding protein; Natalizumab; Oxidative stress; Relapsing-remitting multiple sclerosis

Mesh:

Substances:

Year:  2017        PMID: 27718209      PMCID: PMC5233624          DOI: 10.1007/s13311-016-0480-0

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  61 in total

1.  Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

Authors:  Martin Gunnarsson; Clas Malmeström; Markus Axelsson; Peter Sundström; Charlotte Dahle; Magnus Vrethem; Tomas Olsson; Fredrik Piehl; Niklas Norgren; Lars Rosengren; Anders Svenningsson; Jan Lycke
Journal:  Ann Neurol       Date:  2010-12-08       Impact factor: 10.422

Review 2.  Redox signaling mediated by the gut microbiota.

Authors:  Andrew S Neish
Journal:  Free Radic Res       Date:  2013-10-04

Review 3.  Monoclonal antibodies in MS: mechanisms of action.

Authors:  Bibiana Bielekova; Brenda L Becker
Journal:  Neurology       Date:  2010-01-05       Impact factor: 9.910

4.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

Review 5.  The love-hate relationship between bacterial polysaccharides and the host immune system.

Authors:  Sarkis K Mazmanian; Dennis L Kasper
Journal:  Nat Rev Immunol       Date:  2006-10-06       Impact factor: 53.106

6.  Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis.

Authors:  Lena Melamud; Daniel Golan; Rafael Luboshitzky; Idit Lavi; Ariel Miller
Journal:  J Neurol Sci       Date:  2011-12-01       Impact factor: 3.181

Review 7.  Multiple sclerosis: a battle between destruction and repair.

Authors:  Jonathan L McQualter; Claude C A Bernard
Journal:  J Neurochem       Date:  2006-11-13       Impact factor: 5.372

Review 8.  Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.

Authors:  Corinna Trebst; Elke Voss; Thomas Skripuletz; Martin Stangel
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

9.  Increased cerebrospinal fluid and plasma levels of ultraweak chemiluminescence are associated with changes in the thiol pool and lipid-soluble fluorescence in multiple sclerosis: the pathogenic role of oxidative stress.

Authors:  V Calabrese; R Bella; D Testa; F Spadaro; A Scrofani; V Rizza; G Pennisi
Journal:  Drugs Exp Clin Res       Date:  1998

10.  Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment.

Authors:  Mathilde S A Deloire; Tarik Touil; Bruno Brochet; Vincent Dousset; Jean-Marie Caillé; Klaus G Petry
Journal:  Mult Scler       Date:  2004-10       Impact factor: 6.312

View more
  18 in total

1.  Can Our Guts Tell Us Anything About MS?

Authors:  Carlos R Camara-Lemarroy
Journal:  J Neuroimmune Pharmacol       Date:  2019-02-15       Impact factor: 4.147

2.  Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.

Authors:  Zinah Zamil Al-Ghezi; Philip Brandon Busbee; Hasan Alghetaa; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  Brain Behav Immun       Date:  2019-07-26       Impact factor: 7.217

3.  Aging-Exacerbated Acute Axon and Myelin Injury Is Associated with Microglia-Derived Reactive Oxygen Species and Is Alleviated by the Generic Medication Indapamide.

Authors:  Nathan J Michaels; Kennedy Lemmon; Jason R Plemel; Samuel K Jensen; Manoj K Mishra; Dennis Brown; Khalil S Rawji; Marcus Koch; V Wee Yong
Journal:  J Neurosci       Date:  2020-10-15       Impact factor: 6.167

4.  Neuroinflammation in obesity: circulating lipopolysaccharide-binding protein associates with brain structure and cognitive performance.

Authors:  J M Moreno-Navarrete; G Blasco; J Puig; C Biarnés; M Rivero; J Gich; F Fernández-Aranda; J Garre-Olmo; L Ramió-Torrentà; Á Alberich-Bayarri; F García-Castro; S Pedraza; W Ricart; J M Fernández-Real
Journal:  Int J Obes (Lond)       Date:  2017-07-07       Impact factor: 5.095

Review 5.  The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics.

Authors:  Carlos R Camara-Lemarroy; Luanne Metz; Jonathan B Meddings; Keith A Sharkey; V Wee Yong
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

Review 6.  Targeting the gut to treat multiple sclerosis.

Authors:  Laura Ghezzi; Claudia Cantoni; Gabriela V Pinget; Yanjiao Zhou; Laura Piccio
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

Review 7.  Influence of immunomodulatory drugs on the gut microbiota.

Authors:  Inessa Cohen; William E Ruff; Erin E Longbrake
Journal:  Transl Res       Date:  2021-01-27       Impact factor: 10.171

8.  Go-sha-jinki-Gan Alleviates Inflammation in Neurological Disorders via p38-TNF Signaling in the Central Nervous System.

Authors:  Shiying Jiang; Kousuke Baba; Keisuke Hagihara; Hideki Mochizuki; Tatsusada Okuno; Makoto Kinoshita; Chi-Jing Choong; Hideki Hayakawa; Hiroshi Sakiyama; Kensuke Ikenaka; Seiichi Nagano; Tsutomu Sasaki; Munehisa Shimamura; Yoshitaka Nagai
Journal:  Neurotherapeutics       Date:  2020-10-20       Impact factor: 7.620

9.  The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy.

Authors:  Bożena Adamczyk; Sławomir Wawrzyniak; Sławomir Kasperczyk; Monika Adamczyk-Sowa
Journal:  Oxid Med Cell Longev       Date:  2017-09-12       Impact factor: 6.543

Review 10.  Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System.

Authors:  Kim M A De Kleijn; Gerard J M Martens
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.